Key clinical point: For patients with inflammatory bowel disease, clinicians frequently increase doses of tumor necrosis factor inhibitors without objective evidence of active inflammation, despite potential for increased cost and risk of treatment failure.
Major finding: Among patients who had dose increases, only 24.7% had objective evidence of active inflammation.
Study details: A retrospective study involving 838 patients with inflammatory bowel disease.
Disclosures: The investigators disclosed relationships with AbbVie, Ferring, Janssen, and others.
Elias ED et al. J Clin Gastroenterol. 2020 Jul 17. doi: 10.1097/MCG.0000000000001391.